Lipid-Lowering Potency and Tolerability of Generic Rosuvastatin in Bulgarian Patients with High and Very High Risk

@article{Naydenov2014LipidLoweringPA,
  title={Lipid-Lowering Potency and Tolerability of Generic Rosuvastatin in Bulgarian Patients with High and Very High Risk},
  author={S. Naydenov and N. Runev and E. Manov and R. Shabani and T. Donova},
  journal={Journal of Cardiovascular Diseases and Diagnosis},
  year={2014},
  volume={2},
  pages={1-6}
}
Background: Statins are a class of drugs for treatment of dyslipidemias, but they are also known to significantly reduce the cardiovascular morbidity and mortality in patients at high cardiovascular risk. The objective of our study was to assess the lipid-lowering potency and tolerability of generic rosuvastatin ROSWERA®, prescribed to patients at high and very high cardiovascular risk, with or without hypercholesterolemia. Methods: Forty-five consecutive patients (24 females, 53.3%), mean age… Expand

References

SHOWING 1-10 OF 33 REFERENCES
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
  • L. Lopez
  • Medicine
  • Journal of the American Pharmacists Association : JAPhA
  • 2005
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Clinical efficacy and safety of statins in managing cardiovascular risk
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
...
1
2
3
4
...